

News Release

December 3, 2021

Co-promotion agreement for VMAT2 inhibitor MT-5199 in Japan with Janssen Pharmaceutical K.K.

Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka; President & Representative Director: Hiroaki Ueno) today announced that MTPC and Janssen Pharmaceutical K.K. (Janssen, Head Office: Chiyoda-ku, Tokyo; President: Shuhei Sekiguchi,) concluded a co-promotion agreement for MT-5199 (generic name: valbenazine), a vesicular monoamine transporter type 2 (VMAT2) inhibitor, for the treatment of tardive dyskinesia in Japan on November 30th, 2021.

In April 2021, MTPC filed an application for marketing authorization in Japan of MT-5199 to the Ministry of Health, Labour and Welfare. Under the terms of this agreement, MTPC will obtain approval for this indication and Janssen will be responsible for distribution. Both companies will jointly promote valbenazine.

MTPC believes that by co-promoting with Janssen, who has a track record in the psychiatry area, we will be able to provide appropriate information to more healthcare professionals. Through this collaboration, both companies will contribute to the treatment of patients with tardive dyskinesia.

Tardive dyskinesia is a type of involuntary movement arising from the long-term administration of certain mental health medicines, such as antipsychotic drugs, but the exact pathogenesis has not been determined. Increased sensitivity of dopamine receptors is considered to be a causal factor. Symptoms, including uncontrollable, abnormal and repetitive movements of the tongue, lips, jaw, face, the limbs and torso, differ by patient. Severe cases can lead to dysphagia or respiratory distress, which can be serious in some patients. Since there is currently no approved treatment for tardive dyskinesia in Japan, MTPC would like to bring valbenazine to patients as soon as possible after obtaining regulatory approval.

MTPC will continue to actively pursue R&D opportunities in pharmaceuticals that address unmet medical needs to provide “Creating hope for all facing illness.”.

Mitsubishi Tanabe Pharma Corporation
Communication Crossroads Department

Media contacts: TEL: +81 6 6205 5119

A member of Mitsubishi Chemical Holdings Group.

KAITEKI Value for Tomorrow
Mitsubishi Chemical Holdings Group

<Reference>

About MT-5199

MT-5199 (generic name: valbenazine) is thought to work by selectively inhibiting VMAT2 (vesicular monoamine transporter type 2), which is located in nerve endings, thereby reversibly reducing dopamine secretion from the nerve terminals, and consequently reducing the involuntary movements associated with tardive dyskinesia.

In the U.S., approval for an indication of tardive dyskinesia was received by Neurocrine Biosciences, Inc., in April 2017.